Ariceum Therapeutics Wins Deal of the Year (<€500M) Award at the LSX Leaders European Lifestars Awards

Ariceum Therapeutics was delighted to be presented with the Deal of the Year (<€500M) Award at this year’s LSX Leaders European Lifestars Awards for its strategic research collaboration with UCB! The agreement is to identify and develop novel systemic targeted radiopharmaceuticals for the treatment of solid tumors and immune-related diseases. Ariceum celebrated among a wealth of talented and innovative companies and individuals recognised for their contribution in many areas.

Ariceum’s Chief Executive Officer Manfred Rüdiger (right) celebrates with Chief Business Officer Serge Sagodira (left)